Announcing Public Initiative

Tenuity is proud to launch the first public initiative in our mission to accelerate innovation in under-recognized conditions: Hereditary Alpha-Tryptasemia (HAT).

This initiative calls on innovators, scientists, clinicians, patient-advocates, and partners from across the health ecosystem to join us in a collaborative effort to transform understanding, diagnosis, and treatment pathways.

  • Hereditary Alpha-Tryptasemia (HAT) is a genetic trait characterized by increased copies of the TPSAB1 gene, which leads to elevated levels of basal serum tryptase.

    • Prevalence: Affects ~4–6% of the population.

    • Genetic Cause: Extra copies of the TPSAB1 gene encoding alpha-tryptase.

    • Clinical Impact:

      • Individuals may be asymptomatic or experience symptoms including allergic reactions, gastrointestinal discomfort, autonomic symptoms, and increased risk for severe anaphylaxis.

      • HAT is also a modifying factor in mast cell activation and related disorders.

    Despite its relatively common prevalence, clinical awareness, diagnosis, and therapeutic strategies remain limited, creating an urgent need for coordinated research and innovation.

  • Today, there are no targeted treatments for HAT, and many affected individuals are underdiagnosed or misdiagnosed. Enhanced understanding and collaboration could:

    • Advance diagnostic tools

    • Accelerate research into targeted therapies

    • Improve clinical management and patient outcomes

    • Catalyze innovation in precision medicine

    This aligns with the spirit of breakthrough programs in rare and genetic disease research where cross-sector collaboration yields progress faster than isolated efforts.

  • We’re inviting you to join us in this effort, whether you are:

    🔬 A Researcher or Clinician

    • Share insights into the biological mechanisms of HAT

    • Partner on studies that explore genetic, immunologic, and clinical dimensions

    🚀 An Innovator or Biotech Company

    • Develop new diagnostics, biomarkers, or therapy platforms

    • Join collaborative R&D focused on precision genetic tools

    🧑‍🤝‍🧑 Patient-Advocates & Community Leaders

    • Elevate lived experiences and unmet needs

    • Help bridge the gap between scientific discovery and real-world impact

    Together we aim to create a public, collaborative roadmap.

Let’s Work Together

Let’s work together to bring patients, clinicians, researchers, and innovators together to drive meaningful progress in Hereditary Alpha-Tryptasemia.